Please login to the form below

Not currently logged in
Email:
Password:

Lilly drops evacetrapib on failed atherosclerosis trial

Leaves hole in company's late-stage pipeline
Eli Lilly

Eli Lilly has terminated development of its late-stage cardiovascular candidate evacetrapib after it failed to show efficacy in a large-scale trial.

Evacetrapib is a drug in the CETP inhibitor class designed to increase levels of high-density lipoprotein (HDL) cholesterol - which according to some studies has a protective cardiovascular effect.

The decision to terminate the ACCELERATE trial comes after Lilly had already announced a six-month extension to the protocol earlier this year which raised questions about the chances of a positive outcome.

In a statement, the pharma company said the trial's independent data monitoring committee had recommended halting it "due to insufficient efficacy", adding that evacetrapib's development for the treatment of high-risk atherosclerotic cardiovascular disease would now be discontinued.

The news is a big blow to Lilly as it leaves a hole in its late-stage pipeline, even though expectations for the CETP inhibitor class as a whole - once tipped as a blockbuster category - have recently been downsized.

Late-stage failure for Roche's dalcetrapib and Pfizer's torcetrapib after safety issues emerged in clinical trials damaged confidence in the category. However, evacetrapib's failure to show efficacy - even though the drug seemed safe - now suggests prospects are dim.

The outcome also casts a shadow over the other CETP inhibitors that remain in development, including Merck & Co's anacetrapib - currently in a phase III cardiovascular outcomes study called REVEAL- as well as Bristol-Myers Squibb/Simcere's BMS-795311 and Dezima's TA-8995, recently acquired by Amgen.

The decision to discontinue development of evacetrapib will result in a fourth-quarter charge of up to $90m, said Lilly, although chief financial officer Derica Rice said the termination of the programme "does not change our ability to generate long-term growth."

"Our recent string of positive data-readouts and our strong pipeline position us to grow revenue and expand margins through the remainder of this decade," he insisted.

Article by
Phil Taylor

13th October 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Emotion-driven clinical trial marketing: A missed opportunity?
Whether we’re conscious of it or not, our emotions play a huge role in day-to-day decision making. Psychological scientists have long explored emotional influences on decision making. Experts like Herbert...
Virtual Hackathon on Healthcare Innovation: a Customer Story
How participants from 9 different countries in the APAC region were brought together to participate in a pharmaceutical company-wide 3-day virtual "hackathon," with spectacular results....
OPEN Health at the World Orphan Drug Conference USA
Our Director of Rare Disease, Gavin Jones looks forward to his conversation with Emily Crossle & Betsy Bogard at #WODCUSA2020 !...

Infographics